$5185 | SAVE $915 | Single User
$8925 | SAVE $1,575 | Site License
$14450 | SAVE $2,550 | Enterprise License

Ulcerative Colitis Forecast in 8 Major Markets 2016-2026

Ulcerative Colitis Forecast in 8 Major Markets 2016-2026
[Lowest Price Guaranteed: $5,185]

Published by Black Swan Analysis: 01 Feb 2016 | 81313 | In Stock
Related Topics: Delivery , Gas , Osteoporosis , Ulcerative Colitis

Introduction

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Ulcerative Colitis in 8 Major Markets

Ulcerative Colitis (UC) is an inflammatory bowel disease (IBD) causing chronic inflammation in the colon, and is treated as an autoimmune disease. While sharing some features with Crohn's disease, UC is an intermittent disease with periods of symptoms interspersed with asymptomatic periods (generally induced by response to treatment). The disease involves the rectum up to the colon and is classified according to length of colon affected.

This report provides the current prevalent population for Ulcerative Colitis across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Ulcerative Colitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Ulcerative Colitis include:

• Anaemia

• Gastritis

• Colorectal cancer

• Osteoporosis

• Complications from surgery

• Pouchitis

• Toxic megacolon

• Extra-intestinal features (e.g. primary sclerosing cholangitis, erythema nodosum)

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Ulcerative Colitis’s market to target the development of future products, pricing strategies and launch plans.

• Gain further insight into the prevalence of the subdivided types of Ulcerative Colitis and identify patient segments with high potential.

• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

• Provide a level of understanding on the impact from specific co-morbid conditions on Ulcerative Colitis’s prevalent population.

• Identify sub-populations within Ulcerative Colitis which require treatment.

• Gain an understanding of the specific markets that have the largest number of Ulcerative Colitis patients.

Table of Contents
for Ulcerative Colitis Forecast in 8 Major Markets 2016-2026

  • Summary

    Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Ulcerative Colitis in 8 Major Markets

    Ulcerative Colitis (UC) is an inflammatory bowel disease (IBD) causing chronic inflammation in the colon, and is treated as an autoimmune disease. While sharing some features with Crohn's disease, UC is an intermittent disease with periods of symptoms interspersed with asymptomatic periods (generally induced by response to treatment). The disease involves the rectum up to the colon and is classified according to length of colon affected.

    This report provides the current prevalent population for Ulcerative Colitis across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

    Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Ulcerative Colitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

    Main symptoms and co-morbidities for Ulcerative Colitis include:

    • Anaemia

    • Gastritis

    • Colorectal cancer

    • Osteoporosis

    • Complications from surgery

    • Pouchitis

    • Toxic megacolon

    • Extra-intestinal features (e.g. primary sclerosing cholangitis, erythema nodosum)

    This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

    Reason to buy

    • Able to quantify patient populations in global Ulcerative Colitis’s market to target the development of future products, pricing strategies and launch plans.

    • Gain further insight into the prevalence of the subdivided types of Ulcerative Colitis and identify patient segments with high potential.

    • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

    • Provide a level of understanding on the impact from specific co-morbid conditions on Ulcerative Colitis’s prevalent population.

    • Identify sub-populations within Ulcerative Colitis which require treatment.

    • Gain an understanding of the specific markets that have the largest number of Ulcerative Colitis patients.

List Of Tables
in Ulcerative Colitis Forecast in 8 Major Markets 2016-2026

Table of Contents

• List of Tables and Figures

• Introduction

• Cause of the Disease

• Risk Factors & Prevention

• Diagnosis of the Disease

• Variation by Geography/Ethnicity

• Disease Prognosis &Clinical Course

• Key Co-morbid Conditions /Features Associated with the Disease

• Methodology for Quantification of Patient Numbers

• Top-Line Prevalence for Ulcerative Colitis

• Features of Ulcerative Colitis Patients

o Severity and Type of Involvement in UC

o Contributing Factors to UC Development

• Associated Conditions of Ulcerative Colitis

o Skeletal Associated Conditions

o Dermatological Associated Conditions

o Digestive System Related Conditions

o Haematological & Protein Conditions

• Abbreviations used in the Report

• Other Black Swan Analysis Publications

• Black Swan Analysis Online Patient-Based Databases

• Patient-Based Offering

• Online Pricing Data and Platforms

• References

• Appendix




List of Tables

• Severity index for adult UC patients

• Prevalence of Ulcerative Colitis, total (000s)

• Prevalence of Ulcerative Colitis, males (000s)

• Prevalence of Ulcerative Colitis, females (000s)

• Extent of involvement at diagnosis in Ulcerative Colitis patients, total (000s)

• Severity of Ulcerative Colitis at diagnosis in patients, total (000s)

• Smoking status of Ulcerative Colitis patients, total (000s)

• Ulcerative Colitis patients with family history of UC, total (000s)

• Prevalence of osteoporosis in Ulcerative Colitis patients, total (000s)

• Prevalence of peripheral arthritis in Ulcerative Colitis patients, total (000s)

• Prevalence of ankylosing spondylitis in Ulcerative Colitis patients, total (000s)

• Prevalence of oral ulcerations in Ulcerative Colitis patients, total (000s)

• Prevalence of pyoderma gangrenosum in Ulcerative Colitis patients, total (000s)

• Prevalence of primary sclerosing cholangitis in Ulcerative Colitis patients, total (000s)

• Prevalence of gastritis in Ulcerative Colitis patients, total (000s)

• Type of gastritis in Ulcerative Colitis patients, total (000s)

• Prevalence of anaemia in Ulcerative Colitis patients, total (000s)

• Prevalence of elevated CRP in Ulcerative Colitis patients, total (000s)

• Prevalence of elevated ESR in Ulcerative Colitis patients, total (000s)

• Abbreviations and Acronyms used in the report

• USA Prevalence of Ulcerative Colitis by 5-yr age cohort, males (000s)

• USA Prevalence of Ulcerative Colitis by 5-yr age cohort, females (000s)

• France Prevalence of Ulcerative Colitis by 5-yr age cohort, males (000s)

• France Prevalence of Ulcerative Colitis by 5-yr age cohort, females (000s)

• Germany Prevalence of Ulcerative Colitis by 5-yr age cohort, males (000s)

• Germany Prevalence of Ulcerative Colitis by 5-yr age cohort, females (000s)

• Italy Prevalence of Ulcerative Colitis by 5-yr age cohort, males (000s)

• Italy Prevalence of Ulcerative Colitis by 5-yr age cohort, females (000s)

• Spain Prevalence of Ulcerative Colitis by 5-yr age cohort, males (000s)

• Spain Prevalence of Ulcerative Colitis by 5-yr age cohort, females (000s)

• United Kingdom Prevalence of Ulcerative Colitis by 5-yr age cohort, males (000s)

• United Kingdom Prevalence of Ulcerative Colitis by 5-yr age cohort, females (000s)

• Brazil Prevalence of Ulcerative Colitis by 5-yr age cohort, males (000s)

• Brazil Prevalence of Ulcerative Colitis by 5-yr age cohort, females (000s)

• Japan Prevalence of Ulcerative Colitis by 5-yr age cohort, males (000s)

• Japan Prevalence of Ulcerative Colitis by 5-yr age cohort, females (000s)

List Of Figures, Charts and Diagrams
in Ulcerative Colitis Forecast in 8 Major Markets 2016-2026

See List of Tables for the Figures

Additional Details

Publisher

Black Swan Analysis

Publisher Information

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we’ve seen what works and what doesn’t and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today’s complex healthcare marketplace.



The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.



We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.



The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.



Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Reference

81313 | UCLO0010216

Number of Pages

42

Report Format

PDF

Black Swan Analysis Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 15% today! Ulcerative Colitis - Pipeline Review, H1 2017
Ulcerative Colitis - Pipeline Review, H1 2017SummaryGlobal Markets Direct's latest Pharmaceutical an...
09 May 2017 by Global Markets Direct USD $1,700 (normally
USD $2,000)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Apr 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2017
The Global Ulcerative Colitis Partnering Terms and Agreements since 2010 report provides understandi...
01 Feb 2017 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Global Ulcerative Colitis Partnering 2010-2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,271 (normally
USD $1,495)
More Info
SAVE 15% today! Ulcerative Colitis Global Clinical Trials Review, H2, 2016
Ulcerative Colitis Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial report,...
28 Sep 2016 by Global Data USD $2,125 (normally
USD $2,500)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Are UC biosimilars a real or perceived threat to branded drugs?Ulcerative colitis (UC) treatment is ...
01 Sep 2016 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $846 (normally
USD $995)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
Introductionipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But w...
01 Dec 2015 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info
SAVE 15% today! Ulcerative Colitis: KOL Insight
IntroductionThe Ulcerative Colitis (UC) treatment market is already undergoing radical change as new...
03 Dec 2014 by FirstWord Pharma USD $6,715 (normally
USD $7,900)
More Info

This report is published by Black Swan Analysis

Black Swan Analysis, founded in 2007, is a unique analysis practice that provides robust valuations and commercialisation plans to optimise products in the healthcare industry. We know what it takes to succeed in this industry -we’ve seen what works and what doesn’t and we are committed to bringing insight and high quality solutions to our clients. In doing so we help them meet the many challenges of today’s complex healthcare marketplace.

The Black Swan team has a unique skill set: the ability to develop dynamic market forecasts and interactive patient flow models using a wide range of data including complex pathological and epidemiological information. As pharmaceutical and healthcare companies are challenged to deliver more specific targets that align with unmet medical needs. These modelling approaches are more commercially focused to meet the requirements of a changing healthcare environment.

We have the capability to provide an immediate and ‘hands-on’ approach with every client and where the right internal expertise is leveraged we can help find your optimal solution. Using our bespoke methodologies and frameworks we seek to assess the most challenging valuations.

The valuation outputs we generate can be easily integrated with any in-house existing financial systems, presentation styles or platforms that may be currently operational. This ensures a faster uptake within the business, enabling resources to be re-directed towards implementing the outputs and leveraging new information.

Our philosophy at Black Swan is to create the right environment using inclusive dialogues and collaboration that enable us to generate outputs that make business decisions clear. Our goal is to provide an unparalleled level of satisfaction and quality for our clients.

Download Free Report Summary PDF

Ulcerative Colitis Forecast in 8 Major Markets 2016-2026 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...